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The Japanese Association for Thoracic Surgery has con-
ducted annual surveys of thoracic surgery throughout Japan
since 1986 to determine the statistics regarding the number
of procedures according to operative category. Here, we
have summarized the results from our annual survey of
thoracic surgery performed during 2015.
As has been done so far, thoracic surgery was classified
into three categories—cardiovascular, general thoracic, and
esophageal surgery—and the patient data were examined
and analyzed for each group. Access to the computerized
data is offered to all members of this Association. We
honor and value all member’s continued professional
support and contributions (Tables 1, 2).
The incidence of hospital mortality was added to the survey
to determine the nationwide status, which has contributed to
the Japanese surgeons to understand the present status of
thoracic surgery in Japan and to make progress to improve
operative results by comparing their work with those of others.
The Association was able to gain a better understanding of
present problems as well as future prospects, which has been
reflected to its activity including education of its members.
Thirty-day mortality (so-called ‘‘operative mortality’’) is
defined as death within 30 days of operation regardless of
the patient’s geographic location and even after the patient
had been discharged from the hospital. Hospital mortality is
defined as death within any time interval after an operation
if the patient had not been discharged from the hospital.
Hospital-to-hospital transfer in the categories of eso-
phageal surgery is not considered discharge: transfer to a
nursing home or a rehabilitation unit is considered hospital
discharge unless the patient subsequently dies of compli-
cations of the operation. On the contrary, hospital-to-hos-
pital transfer after 30 days of operation in the categories of
cardiovascular surgery and general thoracic surgery is
considered discharge because data of national clinical
database (NCD) 2015 were used in this category and
hospital-to-hospital transfer after 30 days of operation is
considered discharge in NCD.
Abstract of the survey
All data regarding cardiovascular surgery and thoracic
surgery were obtained from NCD, whereas data regarding
esophageal surgery were collected from survey question-
naire by The Japanese Association for Thoracic Surgery
forms because NCD of esophageal surgery does not include
non-surgical cases (i.e., patients with adjuvant
chemotherapy or radiation alone). Based on the change in
data aggregation, there are several differences between this
2015 annual report and previous annual reports: the num-
ber of institutions decreased in each category from 578
(2014) to 568 (2015) in cardiovascular, from 762 to 714 in
general thoracic and from 626 to 571 in esophageal sur-
gery. Because more than two departments in the same
institute registered their data to NCD individually, we
cannot calculate correct number of institutes in this survey.
Then, the response rate is not indicated in the category of
cardiovascular surgery (Table 1), and the number of
institutions classified by the operation number is also not
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calculated in the category of cardiovascular surgery
(Table 2).
2015 Final report
(A) Cardiovascular surgery
First, we are very pleased with our colleague’s (member’s)
cooperation to our survey of cardiovascular surgery, which
definitely enhances the quality of this annual report. We are
truly grateful again for the enormous effort put into com-
pleting the NCD at each participating institution.
Figure 1 shows the development of cardiovascular sur-
gery in Japan over the last 29 years. Aneurysm surgery
includes only operations for thoracic and thoracoabdominal
aortic aneurysm. Extra-anatomic bypass surgery for tho-
racic aneurysm and pacemaker implantation were totally
excluded from the survey since 2015. The number of assist
device implantation operations is not included in the total
number of surgical operations, while it remained in the
survey. A total of 69,512 cardiovascular operations were
performed at 561 institutions during 2015 alone and
included 44 heart transplantations, which were re-started in
1999.
The number of operations for congenital heart disease
(9054 cases) decreased in 2.3% compared with that of 2014
(9269 cases) [1], and 2.5% decrease when compared with
the data of 10 years ago (9287 cases in 2005) [2]. The
number of operations for adult heart disease (19,820 cases
in valvular heart disease, 15,103 ischemic heart disease,
17,444 cases in thoracic aortic aneurysm and 1897 cases
for other procedures) decreased compared with those of
2014 (9.7, 3.4, 0.3 and 10.4%, respectively).
During the last 10 years, the numbers of operations for
adult heart disease increased constantly except for that for
ischemic heart disease (39.1% increase in valvular heart
disease, 23.5% decrease in ischemic heart disease, 101.1%
increase in thoracic aortic aneurysm, and 56.5% increase in
other procedures compared those of 2005 [2]). The con-
comitant coronary artery bypass grafting procedure
(CABG) is not included in ischemic heart disease but
included in other categories such as valvular heart disease
Table 2 Categories subclassified according to the number of opera-
tions performed
Number of operations performed Category
General thoracic surgery
0 12
1–24 66
25–49 120
50–99 190
100–149 138
150–199 80
] 200 108
Total 714
Number of operations performed Esophageal surgery
0 81
1–4 151
5–9 101
10–19 102
20–29 46
30–39 29
40–49 13
] 50 48
Total 571
Table 1 Questionnaires sent out and received back by the end of
December 2015
Sent out Returned Response rate
(A) Cardiovascular surgery – 568 –
(B) General thoracic surgery 736 714 97.0%
(C) Esophageal surgery 610 571 93.6%
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Table 4 (continued)
(C) TMLR (total 0)
Cases 30-day mortality Hospital
mortality
Hospital After discharge
Isolated 0 0 0 0
with CABG 0 0 0 0
Total 0 0 0 0
TMLR transmyocardial laser revascularization
(3) Operation for arrhythmia (total 5765)
Cases 30-day mortality Hospital
mortality
Concomitant operation
Isolated Congenital Valve IHD Others Multiple combination
Hospital After
discharge
2
categories
3
categories
Maze 3795 73 (1.9) 1 (0.03) 108 (2.8) 80 180 3338 607 290 636 49
For WPW 2 0 0 0 0 0 2 0 0 0 0
For ventricular
tachyarrhythmia
40 1 (2.5) 0 2 (5.0) 2 0 15 24 8 8 1
Others 1928 35 (1.8) 0 68 (3.5) 122 82 1531 400 214 384 30
Total 5765 109
(1.9)
1 (0.02) 178 (3.1) 204 262 4886 1031 512 1028 80
() % mortality
Except for 106 isolated cases, all remaining 3749 cases are doubly allocated, one for this subgroup and the other for the subgroup corresponding
to the concomitant operations
WPW Wolff–Parkinson–White syndrome, IHD ischemic heart disease
(4) Operation for constrictive pericarditis (total 184)
CPB (?) CPB (-)
Cases 30-day mortality Hospital mortality Cases 30-day mortality Hospital mortality
Hospital After discharge Hospital After discharge
Total 96 10 (10.4) 0 17 (17.7) 88 5 (5.7) 0 7 (8.0)
() % mortality
CPB cardiopulmonary bypass
(5) Cardiac tumor (total 560)
Cases 30-day mortality Hospital mortality Concomitant operation
Hospital After discharge AVR MVR CABG others
Benign tumor (cardiac myxoma) 465 2 (0.4) 0 6 (1.3) 10 7 32 82
347 1 (0.3) 0 4 (1.2) 8 4 22 53
Malignant tumor (primary) 95 9 (9.5) 1 (1.1) 12 (12.6) 0 3 3 15
29 3 (10.3) 1 (3.4) 3 (10.3) 0 1 2 7
(), % mortality
AVR aortic valve replacement, MVR mitral valve replacement, CABG coronary artery bypass grafting
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and thoracic aneurysm in our study, then, the number of
CABG still remained over 20,000 cases per year (20,785
cases) in 2015. Data for individual categories are summa-
rized in Tables 3, 4, 5, 6, 7, 8 and 9.
In 2015, 6894 open-heart operations for congenital heart
disease were performed with overall hospital mortality of
2.7%. The number of operations for congenital heart dis-
ease decreased gradually throughout these 10 years (max-
imum 7386 cases in 2006), and overall hospital mortality
showed plateau around 3.0%. In detail, the most common
disease was ventricular septal defect (1253 cases), for the
first time since the inauguration of this survey. Atrial septal
defect (ASD), which had been the most common disease,
was the ‘‘second’’ common one (1031 cases) in 2015. It
was mainly due to the development of catheter device for
ASD closure commercially available in Japan since 2005.
In the last 10 years, hospital mortality for complex con-
genital heart disease was as follows (2005 [2], 2010 [3],
and 2015): complete atrio-septal defect (4.7, 4.2 and 1.7%),
tetralogy of Fallot (1.6, 0.8 and 1.3%), transposition of the
great arteries with intact septum (6.2, 4.1 and 6.6%) and
with ventricular septal defect (15.9, 7.3 and 3.9%), single
ventricle (5.3, 7.5 and 4.3%), and hypoplastic left heart
syndrome (24.4, 13.1 and 9.8%). Right heart bypass
surgery is now commonly performed (364 bidirectional
Glenn procedures excluding 48 Damus–Kaye–Stansel
procedures and 370 Fontan type procedures including total
cavopulmonary connection) with acceptable hospital mor-
tality (1.6 and 2.4%). Norwood type I procedure was per-
formed in 145 cases with relatively low hospital mortality
rate of 14.5%.
The number of operations for valvular heart disease has
constantly increased until 2014 (21,939 cases) [1], and that
was 19,820 cases in 2015. The hospital mortality of pri-
mary single valve placement was 2.8 and 8.7% for the
aortic and the mitral position, while that for primary mitral
valve repair was 1.7%. Hospital mortality rate for redo
valve surgery was 5.7% in aortic and 7.1% in mitral
positions, respectively. Finally, overall hospital mortality
did not show dramatic improvement during the last
10 years (3.6% in 2005 [2], 3.1% in 2010 [3], and 4.0% in
2015), which might be partially due to the recent pro-
gression of age of the patients. Repair of the valve became
a popular procedure (377 cases in the aortic, 6417 cases in
the mitral, and 4942 cases in the tricuspid), and mitral
valve repair constituted 32.4% of all valvular operations
and 65.0% of all mitral valve procedures, which are similar
to those of the last 5 years. Aortic and mitral valve
Table 4 (continued)
(6) HOCM and DCM (total 304)
Cases 30-day mortality Hospital mortality Concomitant operation
Hospital After discharge AVR MVR MVP CABG
Myectomy 139 6
(4.3)
0 10
(7.2)
73 33 16 20
Myotomy 4 0 0 0 1 0 1 1
No resection 144 7
(4.9)
0 15
(10.4)
27 63 81 16
Volume reduction surgery of the left ventricle 17 0 0 2
(11.8)
0 1 13 4
Total 304 13
(4.3)
0 27
(8.9)
101 97 111 41
(), % mortality
HOCM hypertrophic obstructive cardiomyopathy, DCM dilated cardiomyopathy, AVR aortic valve replacement, MVR mitral valve replacement,
MVP mitral valve repair, CABG coronary artery bypass grafting
(7) Other open-heart operation (total 669)
Cases 30-day mortality Hospital mortality
Hospital After discharge
Open-heart operation 390 32 (8.2) 0 41 (10.5)
Non-open-heart operation 279 33 (11.8) 1 (0.4) 38 (13.6)
Total 669 65 (9.7) 1 (0.1) 79 (11.8)
(), % mortality
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replacements with bioprosthesis were performed in 6704
cases and 789 cases, respectively. The ratio of biopros-
thesis was 76.4% at the aortic and 23.8% at the mitral
position. This ratio of the aortic bioprosthesis increased
dramatically from 30 to 40% in the early 2000s [4, 5] to
more than 70% recent 5 years. CABG as a concomitant
procedure was performed in 20.8% of operations for all
valvular heart disease (14.4% in 2005 [2] and 17.3% in
2010 [3]).
Isolated CABG was performed in 13,830 cases which
were only 75.4% of that of 10 years ago (2005 [2]).
Among these, off-pump CABG was intended in 8685
cases (63.0%) with a success rate of 97.2%, so final suc-
cess rate of off-pump CABG was 61.1%. The percentage
of intended off-pump CABG reached 60.3% in 2004 [4]
and then was kept over 60% until now. In 13,830 isolated
CABG patients, 96.8% of them received at least one
arterial graft, while all arterial graft CABGs were
performed only in 22.9% of them. The operative and
hospital mortality rates associated with primary elective
CABG procedures in 11,266 cases were 0.8 and 1.5%,
respectively. Similar data analysis of CABG including
primary/redo and elective/emergency data was begun in
2003 [5], and the operative and hospital mortality rates
associated with primary elective CABG procedures in
2003 were 1.0 and 1.5%, respectively, so operative results
of primary CABG have been stable. Hospital mortality of
primary emergency CABG in 2367 cases was still high
and was 7.4%. The result of conversion from off-pump
CABG rate was 2.8% and hospital mortality in that was
11.3%. A total of 1273 patients underwent surgery for
complications of myocardial infarction, including 272
operations for left ventricular aneurysm, ventricular septal
perforation or cardiac rupture and 340 operations for
ischemic mitral regurgitation.
Operations for arrhythmia were performed mainly as a
concomitant procedure in 5765 cases associated with
49.5% increase comparing with that of 2014. The hospital
mortality of arrhythmia surgery including 3795 MAZE
procedures was 3.1%. MAZE procedure has become quite
popular procedure (2497 cases in 2005 [2] and 3591 cases
in 2010 [3]).
Operations for thoracic aortic dissection were performed
in 8691 cases and this increased by 12.4% this year com-
pared with those of last year. For 6575 Stanford type A
acute aortic dissections, hospital mortality remained high
and was 9.9%. Operations for a non-dissected thoracic
Table 6 Pulmonary thromboembolism (total 134)
Cases 30-day mortality Hospital mortality
Hospital After discharge
Acute 75 18 (24.0) 0 19 (25.3)
Chronic 59 0 0 0
Total 134 18 (13.4) 0 19 (14.2)
( ), % mortality
Table 7 Assisted circulation (total 1637)
Sites VAD Heart–lung assist
Device Results Method Results
Centrifugal VAS
(extra)
VAS
(implant)
Not weaned Weaned PCPS Others Not weaned Weaned
On
going
Death Transplant Alive Deaths Transplant Deaths Transplant Deaths Alive
Post-cardiotomy
Left 13 4 2 3 9 (47.4) 0 12 4 (21.1) 0
Right 8 0 0 0 2 (25.0) 0 5 1 0
Biventricle
Right 4 0 0 0 3 (75.0) 0 1 0 (0.0) 0 485 99 269
(46.1)
0 87
(14.9)
228
Left 2 2 0
Congestive heart failure
Left 61 37 135 131 57
(24.5)
1 41 15 (6.4) 2
Right 4 0 0 1 0 (0.0) 0 2 0 (0.0) 1
Biventricle
Right 24 10 2 8 18
(50.0)
0 7 2 (5.6) 1 624 30 326
(49.8)
2 90
(13.8)
236
Left 17 19 0
Respiratory
failure
80 40 35
(29.2)
0 16
(13.3)
44
Total 133 72 139 143 89
(25.9)
1 68 22 (6.4) 4 1189 169 630
(46.4)
2 193
(14.2)
508
( ), % mortality
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aneurysm were carried out in 9226 cases (decreased by
5.6%), with overall hospital mortality of 6.0%. The hos-
pital mortality associated with unruptured aneurysm was
4.5%, and that of ruptured aneurysm was 24.2%, which
remains markedly high.
The number of stent graft procedures remarkably
increased recently. A total of 2521 patients with aortic
dissection underwent stent graft placement: thoracic
endovascular aortic repair (TEVAR) in 1650 cases and
open stent grafting in 871 cases. The number of TEVAR
for type B chronic aortic dissections increased from 835
cases in 2014 to 1065 cases in 2015. The hospital mortality
rates associated with TEVAR for type B aortic dissection
were 8.9% in acute cases and 2.6% for chronic cases,
respectively.
A total of 3935 patients with non-dissected aortic
aneurysm underwent stent graft placement: TEVAR in
2912 cases (17.3% decrease compared with that in 2014)
and open stent grafting in 937 cases (155% increase
compared with that in 2014). The reason of striking
increase of open stent grafting might be due to commercial
availability since 2014. The hospital mortality rates for
TEVAR and open stenting were as follows: TEVAR (3.2%
for unruptured, 21.7% for ruptured aneurysm,) and open
stenting (7.2% for unruptured and 25.6% for ruptured.)
In summary, the total cardiovascular operations
decreased during 2015 by 2933 cases with steadily constant
results in almost all categories. The main reason why the
number of operations decreased in 2015 was the number of
extra-anatomical bypass operations in thoracic aortic
aneurysm and the number of trans-venous pacemaker
implantations was excluded from the total number of car-
diovascular operations in association with the change of
data aggregation as was referred to earlier.
(B) General thoracic surgery
The 2015 survey of general thoracic surgery comprised 736
surgical units, and most data were submitted using the web-
based collection system of the national clinical database
Table 8 Heart transplantation (total 44)
Cases 30-day mortality Hospital
mortality
Hospital After
discharge
Heart transplantation 44 0 0 0
Heart and lung
transplantation
0 0 0 0
Total 44 0 0 0
( ), % mortality
Table 9 Pacemaker ? ICD (total 4078)
Pacemaker ICD
V A–V CRT CRTD ICD
Initial 442 1700 66 158 251
Exchange 350 862 45 93 111
Unclear 0 0 0 0 0
Total 792 2562 111 251 362
㻜
㻝㻜㻜㻜㻜
㻞㻜㻜㻜㻜
㻟㻜㻜㻜㻜
㻠㻜㻜㻜㻜
㻡㻜㻜㻜㻜
㻢㻜㻜㻜㻜
㻣㻜㻜㻜㻜
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Fig. 2 General thoracic surgery
Table 10 Total entry cases of General Thoracic Surgery during 2015
Cases %
Benign pulmonary tumor 2161 2.7
Primary lung cancer 40,302 50.5
Other primary malignant pulmonary tumor 385 0.5
Metastatic pulmonary tumor 8226 10.3
Tracheal tumor 166 0.2
Mesothelioma 635 0.8
Chest wall tumor 677 0.8
Mediastinal tumor 4813 6.0
Thymectomy for MG without thymoma 164 0.2
Inflammatory pulmonary disease 2265 2.8
Empyema 2739 3.4
Bullous disease excluding pneumothorax 416 0.5
Pneumothorax 14,728 18.5
Chest wall deformity 174 0.2
Diaphragmatic hernia including traumatic 36 0.0
Chest trauma excluding diaphragmatic hernia 388 0.5
Lung transplantation 63 0.1
Others 1437 1.8
Total 79,775 100.0
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(NCD) [1]. In total, 79,775 operations were reported by
general thoracic surgery departments in 2015—1.8 times
the number of operations in 2001 and 2705 more opera-
tions than in 2014 (Fig. 2).
In 2015, 40,302 operations for primary lung cancer were
performed (Table 10), and the number has increased every
year. The 2015 value is 2.1 times that of 2001. Operations
for lung cancer were 50.5% of all procedures in general
thoracic surgery.
The number of video-assisted thoracic surgery (VATS)
procedures in the NCD unexpectedly increased in 2014;
however, the exact number of such procedures was not
published. The increase was attributed to the use of a non-
standard definition of VATS for the NCD registry until
2013. The NCD registry previously included VATS pro-
cedures utilizing a skin incision longer than 8 cm and/or a
minithoracotomy (hybrid) approach, which are tradition-
ally not regarded as VATS procedures. In this report, the
traditional VATS definition is used to describe the number
of VATS procedures in the NCD. The number of VATS
operations for benign pulmonary tumor, primary lung
cancer, and the total number of VATS operation in 2014
and 2015 are shown in Tables 11, 12, 14, 17, 18, 19, 20,
21, 22, 23, 24, 26, 27, 28, and 30, respectively.
There were 2161 operations for benign pulmonary
tumors in 2015, which was similar to the number in 2014
(Table 11). Hamartoma was the most frequent diagnosis in
operations for benign pulmonary tumors. VATS was per-
formed in 2063 patients (95.5%). Additional information
on primary malignant pulmonary tumors is shown in
Tables 12 and 13. With regard to lung cancer subtype,
adenocarcinoma was by far the most frequent diagnosis
(70.0% of all lung cancer operations), followed by squa-
mous cell carcinoma (19.0%). Sublobar resection was
performed in 10,040 lung cancer cases (24.9% of all cases)
and lobectomy was performed in 29,323 cases (72.8% of
all cases). Sleeve lobectomy was performed in 541 cases,
and pneumonectomy was required in 533 cases (1.3% of all
cases). VATS lobectomy for lung cancer was performed in
18,078 cases (61.7%). The number of VATS procedures for
primary lung cancer was slightly higher than in 2014.
In total, 129 patients died before hospital discharge
within 30 days after lung cancer surgery, and 45 patients
died after discharge within 30 days after lung cancer sur-
gery. Therefore, 174 patients died within 30 days after lung
cancer surgery (30-day mortality rate, 0.43%). In total, 277
patients died before discharge (hospital mortality rate,
0.69%), and the 30-day mortality rate, by procedure, was
0.26% for segmentectomy, 0.44% for lobectomy, and
2.44% for pneumonectomy. Interstitial pneumonia was the
leading cause of death after lung cancer surgery, followed
Table 11
1. Benign pulmonary tumor
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
Hamartoma 478 0 0 0 469 454
Sclerosing hemangioma 125 0 0 0 118 96
Papilloma 20 0 0 0 19 16
Mucous gland adenoma bronchial 5 0 0 0 5 7
Fibroma 166 0 0 0 162 128
Lipoma 10 0 0 0 8 6
Neurogenic tumor 15 0 0 0 13 16
Clear cell tumor 4 0 0 0 4 2
Leiomyoma 10 0 0 0 10 16
Chondroma 6 0 0 0 6 4
Inflammatory myofibroblastic tumor 3 0 0 0 3 1
Pseudolymphoma 23 0 0 0 22 31
Histiocytosis 20 0 0 0 19 22
Teratoma 8 0 0 0 5 0
Others 1268 1 (0.1) 0 3 (0.2) 1200 1266
Total 2161 1 (0.0) 0 3 (0.1) 2063 2065
( ) Mortality %
*Unpublished reference data
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by pneumonia, respiratory failure, and cardiovascular
events, as was the case in 2014.
Operations for metastatic pulmonary tumors are shown
in Table 14; 8226 such operations were performed in 2015,
an increase from the previous year. Colorectal cancer was
the most frequent diagnosis (47.2% of all cases).
There were 127 operations for malignant tracheal tumor
in 2015, but only 16 patients were treated with curative
intent (Table 15).
There were 635 pleural tumors in 2015 (Table 16).
Diffuse malignant pleural mesothelioma was the most
frequent histologic diagnosis. Total pleurectomy was per-
formed in 89 cases and extrapleural pneumonectomy in 80
cases. The hospital mortality rate was 4.5% after total
pleurectomy and 5.0% after extrapleural pneumonectomy.
In total, 677 chest wall tumors were resected in 2015
(Table 17); 352 (52.0%) were benign. Among the 325
malignant chest wall tumors, 195 (60.0%) were metastatic
tumors.
Mediastinal tumors were resected in 4813 patients, a
slight increase from the previous year (Table 18). Thymic
epithelial tumor—including 1912 thymomas, 336 thymic
carcinomas, and 30 thymic neuroendocrine carcinomas—
was the most frequent mediastinal tumor type in 2015.
Thymectomy for myasthenia gravis was performed in
474 cases (Table 19); 310 cases were associated with
Table 12
2. Primary malignant pulmonary tumor
Cases Hospital After discharge Hospital mortality By VATS
2015 2014*
2. Primary malignant pulmonary tumor
Lung cancer 40,687 129 (0.3) 45 (0.1) 275 (0.7) 26,188 24,306
Adenocarcinoma 28,206 47 (0.2) 21 (0.1) 87 (0.3)
Squamous cell carcinoma 7651 60 (0.8) 15 (0.2) 132 (1.7)
Large cell carcinoma 744 5 (0.7) 1 (0.1) 14 (1.9)
(LCNEC) 465 2 (0.4) 0 10 (2.2)
Small cell carcinoma 707 6 (0.8) 0 11 (1.6)
Adenosquamous carcinoma 583 3 (0.5) 1 (0.2) 6 (1.0)
Carcinoma with pleomorphic, sarcomatoid
or sarcomatous elements
473 3 (0.6) 5 (1.1) 7 (1.5)
Carcinoid 237 1 (0.4) 0 1 (0.4)
Carcinomas of salivary gland type 35 0 0 0
Unclassified 54 1 (1.9) 0 2 (3.7)
Multiple lung cancer 1245 3 (0.2) 0 11 (0.9)
Others 367 0 2 (0.5) 2 (0.5)
Wedge resection 5810 10 (0.2) 4 (0.1) 25 (0.4) 4917 4359
Segmental excision 4230 10 (0.24) 1 (0.0) 17 (0.4) 2950 2836
(Sleeve segmental excision) 11 0 0 0 7 7
Lobectomy 29,323 96 (0.3) 33 (0.1) 206 (0.7) 18,078 16,676
(Sleeve lobectomy) 541 4 (0.7) 2 (0.4) 12 (2.2) 75 69
Pneumonectomy 533 7 (1.3) 6 (1.1) 13 (2.4) 55 48
(Sleeve pneumonectomy) 10 0 0 1 (10.0) 0 0
Other bronchoplasty 43 2 (4.7) 1 (2.3) 4 (9.3) 5 5
Pleuropneumonectomy 3 0 0 0 0 0
Others 351 4 (1.1) 0 8 (2.3) 183 202
Unknown 9 0 0 0
Sarcoma 47 0 0 2 (4.3)
AAH 109 0 0 0
Others 229 0 0 0
( ) Mortality %
*Unpublished reference data
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thymoma and the remaining cases were not associated with
thymoma.
There were 2265 cases of lung resection for inflamma-
tory lung diseases (Table 20); 34.2% of the cases were
inflammatory tumors of unknown origin, 22.2% were
atypical mycobacterium infections, and 13.6% were fungal
infections.
The 2739 operations for empyema (Table 21) comprised
1999 cases (73.0%) of acute empyema and 740 cases of
chronic empyema. Bronchopleural fistula was reported in
466 patients (23.3%) with acute empyema and 325 patients
(43.9%) with chronic empyema. The hospital mortality rate
was 16.5% in patients with acute empyema with fistula.
There were 98 operations for descending necrotizing
mediastinitis (Table 22). The hospital mortality rate was
8.2%.
There were 416 operations for bullous diseases
(Table 23). Lung volume reduction surgery was performed
in only 21 patients.
The NCD showed 14,728 operations for spontaneous
pneumothorax (Table 24). The 11,816 operations for pri-
mary pneumothorax comprised 3118 patients (26.4%) who
underwent bullectomy only and 7805 patients (66.1%) who
underwent an additional procedure. There were 2851
operations for secondary pneumothorax. COPD was by far
the most prevalent associated disease (69.5%). The hospital
mortality rate for secondary pneumothorax associated with
COPD was 3.1%.
The 2015 survey reported 174 operations for chest wall
deformity (Table 25). However, this might be an under-
estimate, because the Nuss procedure was more likely to
have been performed in centers not associated with JATS.
Diaphragmatic hernia was treated surgically in 36
patients (Table 26). This figure might be an underestimate,
as some procedures might have been classified as gas-
trointestinal surgery.
The survey reported 388 procedures for chest trauma
excluding iatrogenic injuries (Table 27). The hospital
mortality rate was 6.7%.
Table 28 shows operations for other diseases, including
82 cases of arteriovenous malformation and 90 cases of
pulmonary sequestration.
A total of 63 lung transplantations were performed in
2015 (Table 29): 47 patients received lung transplants from
brain-dead donors and 16 received transplants from living-
related donors. The number of lung transplantation proce-
dures has remained constant for several years.
The number of VATS procedures has increased annu-
ally, reaching 60,735 in 2015 (Table 30).
The details of tracheobronchoplasty, pediatric surgery,
and combined resection of neighboring organs are shown in
Tables 31, 32, 33 and 34.
Table 13 Details of lung cancer operation
Cases
c-Stage (TNM)
Ia 24,563
Ib 7631
IIa 3012
IIb 1777
IIIa 2504
IIIb 160
IV 480
NA 175
Total 40,302
Sex
Male 24,882
Female 15,420
NA 0
Total 40,302
Cause of death
Cardiovascular 21
Pneumonia 40
Pyothorax 5
Bronchopleural fistula 17
Respiratory failure 31
Pulmonary embolism 5
Interstitial pneumonia 99
Brain infarction or bleeding 19
Others 75
Unknown 6
Total 318
p-Stage
0 (pCR) 418
Ia 21,131
Ib 7928
IIa 3280
IIb 2088
IIIa 4020
IIIb 194
IV 1027
NA 216
Total 40,302
Age
\ 20 49
20–29 32
30–39 234
40–49 1066
50–59 3716
60–69 13,276
70–79 16,954
80–89 4912
C 90 62
NA 1
Total 40,302
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Table 15
4. Tracheal tumor
Cases 30-day mortality Hospital mortality
Hospital After discharge
4. Tracheal tumor 166 4 (2.4) 3 (1.8) 6 (3.6)
A. Primary malignant tumor
Histological classification
Squamous cell carcinoma 17 1 (5.9) 1 (5.9) 1 (5.9)
Adenoid cystic carcinoma 21 0 0 0
Mucoepidermoid carcinoma 4 0 0 0
Others 17 0 0 0
Total 59 1 (1.7) 1 (1.7) 1 (1.7)
B. Metastatic/invasive malignant tumor
E.g., invasion of thyroid cancer 68 3 (4.4) 2 (2.9) 5 (7.4)
C. Benign tracheal tumor
Histological classification
Papilloma 1 0 0 0
Adenoma 3 0 0 0
Neurofibroma 0 0 0 0
Chondroma 0 0 0 0
Leiomyoma 4 0 0 0
Others 31 0 0 0
Histology unknown 0 0 0 0
Total 39 0 0 0
Operation
Sleeve resection with reconstruction 13 0 0 1 (7.7)
Wedge with simple closure 2 0 0 0
Wedge with patch closure 0 0 0
Total laryngectomy with tracheostomy 0 0 0 0
Others 1 0 0 0
Unknown 0 0 0 0
Total 16 0 0 1 (6.3)
( ) Mortality %
Table 14
3. Metastatic pulmonary tumor
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
3. Metastatic pulmonary tumor 8226 13 (0.2) 5 (0.1) 25 (0.3) 7593 7424
Colorectal 3886 2 (0.1) 3 (0.1) 6 (0.2) 3589 3618
Hepatobiliary/pancreatic 352 0 1 (0.3) 1 (0.3) 327 332
Uterine 475 0 0 0 446 363
Mammary 474 1 (0.2) 0 1 (0.2) 448 420
Ovarian 74 0 0 0 71 56
Testicular 65 0 0 1 (1.5) 58 77
Renal 653 0 0 0 627 589
Skeletal 118 0 0 0 107 135
Soft tissue 249 1 (0.4) 0 2 (0.8) 219 212
Otorhinolaryngological 460 0 0 2 (0.4) 425 385
Pulmonary 480 3 (0.6) 0 5 (1.0) 394 407
Others 940 6 (0.6) 1 (0.1) 7 (0.7) 882 830
( ) Mortality %
*Unpublished reference data
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Table 16
5. Tumor of pleural origin
5. Tumor of pleural origin Cases 30-day mortality Hospital mortality
Hospital After discharge
Histological classification
Solitary fibrous tumor 116 0 0 0
Diffuse malignant pleural mesothelioma 280 4 (1.4) 3 (1.1) 9 (3.2)
Localized malignant pleural mesothelioma 36 0 0 0
Others 203 1 (0.5) 0 3 (1.5)
Total 635 5 (0.8) 3 (0.5) 12 (1.9)
Operative procedure
Extrapleural pneumonectomy 80 1 (1.3) 0 4 (5.0)
Total pleurectomy 89 2 (2.2) 0 4 (4.5)
Others 111 1 (0.9) 3 (2.7) 1 (0.9)
Total 280 4 (1.4) 3 (1.1) 9 (3.2)
( ) Mortality %
Table 17
6. Chest wall tumor
6. Chest wall tumor Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
Primary malignant tumor 130 0 0 0 54 57
Metastatic malignant tumor 195 0 1 (0.5) 1 (0.5) 62 81
Benign tumor 352 0 0 1 (0.3) 264 274
Total 677 0 1 (0.1) 2 (0.3) 380 412
( ) Mortality %
*Unpublished reference data
Table 18
7. Mediastinal tumor
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
7. Mediastinal tumor 4813 3 (0.1) 3 (0.06) 9 (0.2) 3369 3208
Thymoma* 1912 2 (0.1) 0 3 (0.2) 1127 1016
Thymic cancer 336 0 0 1 (0.3) 167 143
Thymus carcinoid 30 0 0 0 20 15
Germ cell tumor 107 0 0 0 58 56
Benign 82 0 0 0 47 47
Malignant 25 0 0 0 11 9
Neurogenic tumor 424 0 1 (0.2) 0 397 440
Congenital cyst 1026 0 0 0 924 811
Goiter 84 1 (1.2) 1 (1.2) 1 (1.2) 24 19
Lymphatic tumor 186 0 0 2 (1.1) 141 155
Excision of pleural recurrence of thymoma 27 0 0 0 23 31
Thymolipoma 15 0 0 0 10 9
Others 666 0 1 (0.2) 2 (0.3) 478 513
( ) Mortality %
*Unpublished reference data
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(C) Esophageal surgery
During 2015 alone, a total of 12,732 patients with eso-
phageal diseases were registered from 571 institutions
(response rate: 93.6%) affiliated to the Japanese Associa-
tion for Thoracic Surgery and/or to the Japan Esophageal
Society. Among these institutions, those where 20 or more
patients underwent esophageal surgeries within the year of
2015 were 136 institutions (23.8%), which shows no defi-
nite shift of esophageal operations to high-volume institu-
tions when compared to the data of 2014 (22.1%)
(Table 35). Of 2991 patients with a benign esophageal
disease, 1619 (54.1%) patients underwent surgery, and 77
(2.6%) patients underwent endoscopic resection, while
1295 (43.3%) patients did not undergo any surgical treat-
ment (Table 36). Of 10,288 patients with a malignant
esophageal tumor, 8106 (78.8%) patients underwent
resection, esophagectomy for 6151 (59.8%) and endo-
scopic mucosal resection (EMR) or endoscopic submucosal
dissection (ESD) for 1955 (19.0%), while 2182 (21.2%)
patients did not undergo any resection (Tables 37, 38). The
patients registered, particularly those undergoing non-sur-
gical therapy for a malignant esophageal disease, have
been increasing since 1990 (Fig. 3).
Among benign esophageal diseases (Table 36), hiatal
hernia, esophageal varices, esophagitis (including reflux
esophagitis) and achalasia were the most common condi-
tions in Japan. On the other hand, spontaneous rupture of
the esophagus, benign esophageal tumors and congenital
esophageal atresia were common diseases which were
surgically treated as well as the above-mentioned diseases.
The thoracoscopic and/or laparoscopic procedures have
been widely adopted for benign esophageal diseases, in
particular achalasia, hiatal hernia and benign tumors. Open
Table 19
8. Thymectomy for myasthenia gravis
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
8. Thymectomy for myasthenia gravis 474 3 (0.6) 0 4 (0.8) 248 269
With thymoma 310 2 (0.6) 0 3 (1.0) 152 161
( ) Mortality %
*Unpublished reference data
Table 20
9. Operations for non-neoplastic disease(A) Inflammatory pulmonary disease
Cases 30-day mortality Hospital mortality
Hospital After discharge
22,183 175 (0.8) 33 (0.1) 428 (1.9)
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
(A) Inflammatory pulmonary disease 2265 8 (0.4) 3 (0.1) 24 (1.1) 2004 1958
Tuberculous infection 68 0 0 0 57 60
Mycobacterial infection 503 0 0 0 449 435
Fungal infection 309 5 (1.6) 0 7 (2.3) 236 249
Bronchiectasis 67 0 0 3 (4.5) 49 54
Tuberculous nodule 106 0 1 (0.9) 0 103 120
Inflammatory pseudo tumor 776 0 1 (0.1) 1 (0.1) 734 508
Interpulmonary lymph node 56 0 0 0 56 59
Others 380 3 (0.8) 1 (0.3) 13 (3.4) 320 473
( ) Mortality %
*Unpublished reference data
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surgery was performed in 1072 (66.2%) patients with a
benign esophageal disease, with 30-day mortality in 7
(0.7%), while thoracoscopic and/or laparoscopic surgery
was performed for 547 (33.8%) patients, with none of the
30-day mortality. The difference in these death rates
between open and scopic surgery seems to be related to the
conditions requiring open surgery.
The majority of malignant diseases were carcinomas
(Table 37). Among esophageal carcinomas, the incidence
of squamous cell carcinoma was 90.1%, while that of
adenocarcinomas including Barrett cancer was 7.2%. The
resection rate for patients with a squamous cell carcinoma
was 77.9%, while that for patients with an adenocarcinoma
was 88.9%.
According to location, cancer in the thoracic esophagus
was the most common (Table 38). Of the 4137 patients
(40.2% of total esophageal malignancies) having superfi-
cial esophageal cancers within mucosal and submucosal
Table 23
9. Operations for non-neoplastic disease
(D) Bullous disease
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
(D) Bullous disease 416 1 (0.2) 0 2 (0.5) 393 366
Emphysematous bulla 330 1 (0.3) 0 2 (0.6) 314 288
Bronchogenic cyst 16 0 0 0 14 15
Emphysema with volume reduction surgery 21 0 0 0 20 23
Others 49 0 0 0 45 40
LVRS lung volume reduction surgery
( ) Mortality %
Table 22
9. Operations for non-neoplastic
disease
(C) Descending necrotizing
mediastinitis
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
(C) Descending necrotizing mediastinitis
98 2 (2.0) 0 8 (8.2) 70 80
( ) Mortality %
*Unpublished reference data
Table 21
9. Operations for non-neoplastic
disease
(B) Empyema
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
Acute empyema 1999 45 (2.3) 8 (0.4) 131 (6.6) 1657 1574
With fistula 466 27 (5.8) 3 (0.6) 77 (16.5) 275 274
Without fistula 1516 18 (1.2) 5 (0.3) 52 (3.4) 1369 1279
Unknown 17 0 0 2 (11.8) 13 21
Chronic empyema 740 10 (1.4) 2 (0.3) 53 (7.2) 404 368
With fistula 325 5 (1.5) 1 (0.3) 33 (10.2) 126 132
Without fistula 367 5 (1.4) 1 (0.3) 18 (4.9) 248 214
Unknown 48 0 0 2 (4.2) 30 22
Total, % 2739 55 (2.0) 10 (0.4) 184 (6.7) 2061 1942
( ) Mortality %
*Unpublished reference data
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Table 24
9. Operations for non-neoplastic disease
(E) Pneumothorax
Cases 30-day mortality Hospital mortality
Hospital After discharge
14,728 95 (0.6) 17 (0.1) 120 (0.8)
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
Spontaneous pneumothorax
Operative procedure
Bullectomy 3118 6 (0.2) 1 (0.0) 9 (0.3)
3122
3380
Bullectomy with additional procedure 7805 4 (0.05) 3 (0.04) 8 (0.1)
7713
7453
Coverage with artificial material 7409 3 (0.04) 3 (0.0) 7 (0.1)
7327
7059
Parietal pleurectomy 35
0
0 0
33
52
Coverage and parietal pleurectomy 109 1 (0.9) 0 1 (0.9)
105
94
Others 252
0
0 0
248
248
Others 888 4 (0.5) 2 (0.2) 8 (0.9)
799
836
Unknown 5
0
0 0
5
8
Total 11,816 14 (0.1) 6 (0.05) 25 (0.2)
11,639
11,679
Secondary pneumothorax
Associated disease
COPD 1981 33 (1.7) 6 (0.3) 61 (3.1)
1912
1696
Tumorous disease 123 2 (1.6) 3 (2.4) 5 (4.1)
114
79
Catamenial 137 0 0 0
132
146
LAM 50 0 0 0
50
42
Others (excluding pneumothorax by trauma) 560 16 (2.9) 2 (0.4) 29 (5.2)
509
544
Unknown 0 0 0 0
0
0
Operative procedure
Bullectomy 436 11 (2.5) 2 (0.5) 17 (3.9) 422 383
Bullectomy with additional procedure 1665 21 (1.3) 4 (0.2) 42 (2.5) 1616 1416
Coverage with artificial material 1560 21 (1.3) 4 (0.3) 41 (2.6) 1516 1335
Parietal pleurectomy 10 0 0 0 9 7
Coverage and parietal pleurectomy 37 0 0 0 34 16
Others 58 0 0 1 (1.7) 57 58
Others 748 19 (2.5) 5 (0.7) 36 (4.8) 678 690
Unknown 2 0 0 0 1 5
Total 2851 51 (1.8) 11 (0.4) 95 (3.3) 2717 2507
( ) Mortality %
*Unpublished reference data
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layers, 6151 (59.8%) patients underwent esophagectomy,
while 1955 (19.0%) patients underwent EMR or ESD. The
30-day mortality rate and hospital mortality rate after
esophagectomy for patients with a superficial cancer were
0.5 and 1.7% (141/6151), respectively.
Multiple primary cancers were observed in 1816
(17.7%) of all the 10,288 patients with esophageal cancer.
Synchronous cancer was found in 960 (9.3%) patients,
while metachronous cancer was observed in 856 (8.3%)
patients. The stomach is the commonest site for both
Table 25
9. Operations for non-neoplastic disease
(F) Chest wall deformity
Cases 30-day mortality Hospital
mortality
Hospital After
discharge
(F) Chest wall deformity 174 0 0 0
Funnel chest 167 0 0 0
Others 7 0 0 0
( ) Mortality %
Table 26
9. Operations for non-neoplastic disease
(G) Diaphragmatic hernia
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
(G) Diaphragmatic hernia 36 0 0 0 22 24
Congenital 3 0 0 0 3 8
Traumatic 12 0 0 0 7 3
Others 21 0 0 0 12 13
( ) Mortality %
*Unpublished reference data
Table 27
9. Operations for non-neoplastic disease
(H) Chest trauma
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
(H) Chest trauma 388 17 (4.4) 0 26 (6.7) 243 239
( ) Mortality %
*Unpublished reference data
Table 28
9. Operations for non-neoplastic disease
(I) Other respiratory surgery
Cases 30-day mortality Hospital mortality By VATS
Hospital After discharge 2015 2014*
(I) Other respiratory surgery 1339 27 (2.0) 3 (0.2) 64 (4.8) 953 957
Arteriovenous malformation* 82 0 0 0 77 70
Pulmonary sequestration 90 0 0 0 73 89
Postoperative bleeding[ air leakage 385 11 (2.9) 0 27 (7.0) 273 255
Chylothorax 64 2 (3.1) 0 2 (3.1) 55 52
Others 718 14 (1.9) 3 (0.4) 35 (4.9) 475 491
( ) Mortality %
*Unpublished reference data
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synchronous and metachronous malignancy followed by
head and neck cancer (Table 38).
Among esophagectomy procedures, transthoracic
esophagectomy through right thoracotomy was the most
commonly adopted for patients with a superficial cancer as
well as for those with an advanced cancer (Table 39).
Transhiatal esophagectomy commonly performed in Wes-
tern countries was adopted in only 2.8% of patients having
Table 29
10. Lung transplantation
Cases 30-day mortality Hospital mortality
Hospital After discharge
Single lung transplantation from brain-dead donor 23 1 (4.3) 0 2 (8.7)
Bilateral lung transplantation from brain-dead donor 24 0 0 1 (4.2)
Lung transplantation from living donor 16 0 0 1 (6.3)
Total of lung transplantation 63 1 (1.6) 0 4 (6.3)
Donor of living donor lung transplantation 31 0 0 0
( ) Mortality %
Table 30
11. Video-assisted thoracic surgery
Cases 30-day mortality Hospital mortality
Hospital After discharge
11. Video-assisted thoracic surgery 2015 60,735 186 (0.3) 59 (0.10) 396 (0.7)
2014* 58,259 194 (0.3) 43 (0.07) 437 (0.8)
*Unpublished reference data
( ) Mortality % (including thoracic sympathectomy 160)
Table 31
12. Tracheobronchoplasty
Cases 30-day mortality Hospital mortality
Hospital After discharge
12. Tracheobronchoplasty 703 9 (1.3) 5 (0.7) 21 (3.0)
Trachea 29 2 (6.9) 0 2 (6.9)
Sleeve resection with reconstruction 16 0 0 0
Wedge with simple closure 5 0 0 0
Wedge with patch closure 0 0 0 0
Total laryngectomy with tracheostomy 0 0 0 0
Others 8 2 (25.0) 0 2 (25.0)
Carinal reconstruction 33 0 1 (3.0) 0
Sleeve pneumonectomy 11 0 0 1 (9.1)
Sleeve lobectomy 536 5 (0.9) 2 (0.4) 13 (2.4)
Sleeve segmental excision 17 0 0 0
Bronchoplasty without lung resection 14 0 0 0
Others 63 2 (3.2) 2 (3.2) 5 (7.9)
( ) Mortality %
Table 32
13. Pediatric surgery
Cases 30-day mortality Hospital
mortality
Hospital After
discharge
13. Pediatric
surgery
359 4 (1.1) 0 6 (1.7)
( ) Mortality %
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a superficial cancer who underwent esophagectomy and in
1.4% of those having an advanced cancer in Japan. The
thoracoscopic and/or laparoscopic esophagectomy were
adopted for 1036 patients (51.3%) with a superficial
Table 33
14. Combined resection of neighboring organ(s)
Cases 30-day mortality Hospital mortality
Hospital After discharge
14.Combined resection of neighboring organ(s) 1451 7 (0.5) 3 (0.2) 22 (1.5)
Organ resected Cases 30-day mortality Hospital mortality
Hospital After discharge
A. Primary lung cancer
Aorta 8 0 0 0
Superior vena cava 24 0 0 0
Brachiocephalic vein 17 1 (5.9) 0 1 (5.9)
Pericardium 127 1 (0.8) 2 (1.6) 8 (6.3)
Pulmonary artery 129 1 (0.8) 0 2 (1.6)
Left atrium 27 0 0 1 (3.7)
Diaphragm 71 0 0 1 (1.4)
Chest wall (including ribs) 360 3 (0.8) 1 (0.3) 8 (2.2)
Vertebra 11 0 0 1 (9.1)
Esophagus 6 0 0 0
Total 780 6 (0.8) 3 (0.4) 22 (2.8)
B. Mediastinal tumor
Aorta 3 0 0 0
Superior vena cava 72 0 0 1 (1.4)
Brachiocephalic vein 92 0 0 0
Pericardium 355 1 (0.3) 0 2 (0.6)
Pulmonary artery 2 0 0 0
Left atrium 0 0 0 0
Diaphragm 34 0 0 0
Chest wall (including ribs) 7 0 0 0
Vertebra 3 0 0 0
Esophagus 5 0 0 0
Lung 530 1 (0.2) 0 2 (0.4)
Total 1103 2 (0.2) 0 5 (0.5)
( ) Mortality %
Table 34
15. Operation of lung cancer invading the chest wall of the apex
Cases 30-day mortality Hospital
mortality
Hospital After
discharge
15.Operation of lung
cancer invading the
chest wall of the apex
741 2 (0.3) 4 (0.5) 7 (0.9)
( ) Mortality %
Includes tumors invading the anterior apical chest wall and posterior
apical chest wall (superior sulcus tumor, so-called Pancoast type)
Table 35 Distribution of number of esophageal operations in 2015 in
each institution
Esophageal surgery
Number of
operations in
2015
Benign
esophageal
diseases
Malignant
esophageal
disease
Benign ? malignant
0 267 117 81
1–4 241 145 151
5–9 43 108 101
10–19 14 80 102
20–29 3 42 46
30–39 1 26 29
40–49 1 12 13
] 50 1 41 48
Total 571 571 571
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Fig. 3 Annual trend of in-patients with esophageal diseases. EMR endoscopic mucosal resection (including endoscopic submucosal)
Table 37 Malignant esophageal diseases (histologic classification)
Resection (?) Resection (-) Total
Carcinomas 7979 2158 10,137
1. Squamous cell carcinoma 7116 2021 9137
2. Basaloid(-squamous) carcinoma 82 9 91
3. Carcinosarcoma 26 4 30
4. Adenocarcinoma in the Barrett’s esophagus 346 32 378
5. Other adenocarcinoma 302 49 351
6. Adenosquamous carcinoma 20 3 23
7. Mucoepidermoid carcinoma 5 0 5
8. Adenoid cystic carcinoma 2 0 2
9. Endocrine cell carcinoma 46 18 64
10. Undifferentiated carcinoma 5 7 12
11. Others 29 15 44
Other malignancies 42 6 48
1. Malignant non-epithelial tumors 10 1 11
2. Malignant melanoma 25 3 28
3. Other malignant tumors 7 2 9
Not specified 127 24 151
Total 8148 2188 10,336
Resection: including endoscopic resection
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Table 38 Malignant esophageal disease (clinical characteristics)
Operation (?) EMR or ESD Operation (-) Total
Cases Hospital mortality
* 30 days 31–90 days Total (including
after 91-day mortality)
1. Esophageal cancer 6151 39 (0.6) 72 (1.2) 141 (2.3) 1955 2182 10,288
Location
(1) Cervical esophagus 203 1 (0.5) 6 (3.0) 13 (6.4) 68 182 453
(2) Thoracic esophagus 5030 31 (0.6) 61 (1.2) 115 (2.3) 1580 1737 8347
(3) Abdominal esophagus 651 4 (0.6) 3 (0.5) 7 (1.1) 136 100 887
(4) Multiple cancers 260 3 (1.2) 2 (0.8) 6 (2.3) 136 60 456
(5) Others/not described 7 0 0 0 35 103 145
Tumor depth
(A) Superficial cancer (T1) 2019 10 (0.5) 15 (0.7) 34 (1.7) 1952 166 4137
Mucosal cancer (T1a) 434 4 (0.9) 1 (0.2) 6 (1.4) 1544 37 2015
(B) Advanced cancer (T2–T4) 4130 29 (0.7) 56 (1.4) 106 (2.6) 3 2012 6145
(C) Not specified 2 0 1 1 0 4 6
2. Multiple primary cancers 1022 8 (0.8) 11 (1.1) 28 (2.7) 490 304 1816
1) Synchronous 583 5 (0.9) 4 (0.7) 15 (2.6) 202 175 960
(1) Head and neck 164 0 1 (0.6) 3 (1.8) 78 58 300
(2) Stomach 217 2 (0.9) 1 (0.5) 5 (2.3) 71 55 343
(3) Colorectum 71 1 (1.4) 1 (1.4) 3 (4.2) 14 11 96
(4) Lung 26 0 0 0 3 13 42
(5) Pancreas 5 0 0 0 0 3 8
(6) Liver 12 1 (8.3) 0 1 (8.3) 4 1 17
(7) Others 45 1 (2.2) 0 1 (2.2) 8 17 70
(8) Triple cancers 43 0 1 (2.3) 2 (4.7) 22 16 81
(9) Unknown 0 0 0 0 2 1 3
2) Metachronous 439 3 (0.7) 7 (1.6) 13 (3.0) 288 129 856
(1) Head and neck 81 0 0 0 81 15 177
(2) Stomach 99 2 (2.0) 2 (2.0) 5 (5.1) 69 36 204
(3) Colorectum 53 0 1 (1.9) 1 (1.9) 24 16 93
(4) Lung 23 0 0 0 14 8 45
(5) Pancreas 2 0 0 0 0 0 2
(6) Liver 5 0 0 0 4 3 12
(7) Others 145 1 (0.7) 3 (2.1) 6 (4.1) 49 31 225
(8) Triple cancers 31 0 1 (3.2) 1 (3.2) 47 17 95
(9) Unknown 0 0 0 0 0 3 3
Unknown 0 0 0 0 0 0 0
( ), Mortality %
EMR endoscopic mucosal resection (including endoscopic submucosal dissection
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Table 39 Malignant esophageal disease (surgical procedures)
Operation (?) EMR
or
ESD
Thoracoscopic and/or laparoscopic procedure
Cases Hospital mortality Cases Hospital mortality
* 30 days 31–90 days Total (including
after 91-day
mortality)
* 30 days 31–90 days Total (including
after 91-day
mortality)
Superficial cancer (T1) 2019 10 (0.5) 15 (0.7) 34 (1.7) 1306 4 (0.3) 9 (0.7) 16 (1.2) 1952
Mucosal cancer (T1a) 434 4 (0.9) 1 (0.2) 6 (1.4) 260 2 (0.8) 1 (0.4) 3 (1.2) 1544
Esophagectomy 2019 10 (0.5) 15 (0.7) 34 (1.7) 1306 4 (0.3) 9 (0.7) 16 (1.2) 1952
(1) Transhiatal
esophagectomy
57 1 (1.8) 1 (1.8) 2 (3.5) 15 0 0 0
(2) Transthoracic (rt.)
esophagectomy and
reconstruction
1709 7 (0.4) 12 (0.7) 27 (1.6) 1194 3 (0.3) 8 (0.7) 14 (1.2)
(3) Transthoracic (lt.)
esophagectomy and
reconstruction
27 0 0 0 3 0 0 0
(4) Cervical esophageal
resection and
reconstruction
31 1 (3.2) 1 (3.2) 2 (6.5) 15 0 1 (6.7) 1 (6.7)
(5) Two-stage
operation
41 1 (2.4) 0 2 (4.9) 23 1 (4.3) 0 1 (4.3)
(6) Others 135 0 1 (0.7) 1 (0.7) 49 0 0 0
(7) Not specified 19 0 0 0 7 0 0 0
Advanced cancer (T2–T4)
Esophagectomy 4130 29 (0.7) 56 (1.4) 106 (2.6) 1734 12 (0.7) 25 (1.4) 42 (2.4) 3
(1) Transhiatal
esophagectomy
57 1 (1.8) 1 (1.8) 3 (5.3) 12 0 0 0
(2) Transthoracic (rt.)
esophagectomy and
reconstruction
3500 26 (0.7) 46 (1.3) 85 (2.4) 1607 11 (0.7) 22 (1.4) 38 (2.4)
(3) Transthoracic (lt.)
esophagectomy and
reconstruction
105 0 0 1 (1.0) 12 0 0 0
(4) Cervical
esophageal
resection and
reconstruction
137 0 3 (2.2) 8 (5.8) 23 0 2 (8.7) 2 (8.7)
(5) Two-stage
operation
71 1 (1.4) 4 (5.6) 6 (8.5) 16 0 0 0
(6) Others/not
specified
206 1 (0.5) 2 (1.0) 3 (1.5) 58 1 (1.7) 1 (1.7) 2 (3.4)
(7) Not specified 54 0 0 0 6 0 0 0
(Depth not specified) 2 0 1 1 0 0 0 0 0
Combined resection of
other organs
351 7 (2.0) 4 (1.1) 15 (4.3)
(1) Aorta 3 0 0 0
(2) Trachea, bronchus 15 0 0 0
(3) Lung 67 3 (4.5) 0 4 (6.0)
(4) Others 266 4 (1.5) 4 (1.5) 11 (4.1)
Unknown 0 0 0 0
Salvage surgery 264 4 (1.5) 11 (4.2) 21 (8.0) 58 1 (1.7) 1 (1.7) 3 (5.2) 29
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cancer, and for 1734 patients (42.0%) with an advanced
cancer. The number of cases of thoracoscopic and/or
laparoscopic surgery for superficial or advanced cancer has
been increasing for these several years (Fig. 4).
Combined resection of the neighboring organs during
resection of an esophageal cancer was performed in 351
patients (Tables 39, 40). Resection of the aorta together
with esophagectomy was performed in three cases.
Tracheal and/or bronchial resection combined with
esophagectomy was performed in 15 patients, with the both
of 30-day mortality rate and the hospital mortality rate at
0%. Lung resection combined with esophagectomy was
performed in 67 patients, with the 30-day mortality rate at
4.5% and the hospital mortality rate at 6.0%.
Salvage surgery after definitive (chemo-)radiotherapy
was performed in 264 patients, with the 30-day mortality
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Fig. 4 Annual trend of video-assisted esophagectomy for esophageal malignancy
Table 40 Mortality after combined resection of the neighboring organs
Year Esophagectomy Combined resection
Aorta Tracheobronchus Lung Others
a b c (%) a b c (%) a b c (%) a b c (%) a b c (%)
1996 4194 120 2.86 7 3 42.86 24 0 0.00 50 2 4.00 78 4 5.13
1997 4441 127 2.86 1 0 0.00 34 5 14.71 56 1 1.79 94 3 3.19
1998 4878 136 2.79 4 0 0.00 29 0 0.00 74 1 1.35 128 2 1.56
1999 5015 116 2.31 5 0 0.00 23 2 8.70 68 0 0.00 122 1 0.82
2000 5350 81 1.51 2 0 0.00 23 2 8.70 69 0 0.00 96 1 1.04
2001 5521 110 1.99 1 0 0.00 26 1 3.85 83 3 3.61 99 2 2.02
2002 4904 66 1.35 3 1 33.33 20 2 10.00 63 0 0.00 63 1 1.59
2003 4639 45 0.97 0 0 0.00 24 2 8.33 58 0 0.00 88 1 1.14
2004 4739 64 1.35 2 0 0.00 17 0 0.00 59 5 8.47 119 2 1.68
2005 5163 52 1.01 1 0 0.00 11 1 9.09 67 1 1.49 73 1 1.37
2006 5236 63 1.20 0 0 0.00 17 0 0.00 62 2 3.23 122 3 2.46
2007 4990 60 1.20 0 0 0.00 25 1 4.00 44 1 2.27 138 2 1.45
2008 5124 63 1.23 0 0 0.00 17 1 5.88 48 1 2.08 185 0 0.00
2009 5260 63 1.20 0 0 0.00 19 2 10.53 58 2 3.45 211 3 1.42
2010 5180 45 0.87 2 0 0.00 33 0 0.00 58 0 0.00 245 5 2.04
2011 5430 38 0.70 4 0 0.00 26 0 0.00 41 0 0.00 179 5 2.79
2012 6055 47 0.78 2 0 0.00 23 1 4.35 69 0 0.00 240 1 0.42
2013 5824 41 0.70 2 0 0.00 44 0 0.00 77 1 1.30 156 3 1.92
2014 6244 47 0.75 2 0 0.00 24 0 0.00 77 3 3.90 227 3 1.32
2015 6151 39 0.63 3 0 0.00 15 0 0.00 67 3 4.48 266 4 1.50
Total 1,04,338 1423 1.36 41 4 9.76 273 20 7.33 1248 26 2.08 2929 47 1.60
a Number of patients who underwent the operation
b Number of patients died within 30 days after operation
c % ratio of b/a, i.e., direct operative mortality
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rate at 1.5% and with the hospital mortality rate at 8.0%
(Table 39).
Lastly, in spite of the efforts of the Committee to cover
wider patient populations to this annual survey, the
majority of the institutions which responded to the ques-
tionnaire were the departments of thoracic or esophageal
surgery. It should be noted that larger number of patients
with esophageal diseases should have been treated medi-
cally and endoscopically. We should continue our effort for
complete survey through more active collaboration with
the Japan Esophageal Society and other related societies.
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